Rhenman & Partners Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Rhenman & Partners Asset Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-119,400	Closed	-$3.59M	–	102
2025 Q3	$3.59M	Buy	119,400 +26,300	+28%	+$789K	0.4%	67
2025 Q2	$3.39M	Buy	93,100 +11,100	+14%	+$400K	0.43%	61
2025 Q1	$2.97M	Buy	+82,000	New	+$3.41M	0.34%	60
2020 Q4	–	Sell	-61,500	Closed	-$5.05M	–	93
2020 Q3	$5.05M	Hold	61,500	–	–	0.45%	64
2020 Q2	$4.81M	Sell	61,500 -7,024	-10%	-$465K	0.52%	63
2020 Q1	$3.04M	Buy	+68,524	New	+$3.56M	0.43%	67
2018 Q1	–	Sell	-95,000	Closed	-$4.41M	–	97
2017 Q4	$4.41M	Sell	95,000 -5,000	-5%	-$245K	0.6%	60
2017 Q3	$5.33M	Buy	100,000 +64,427	+181%	+$3.82M	0.68%	59
2017 Q2	$2.21M	Buy	+35,573	New	+$2.14M	0.32%	76
2016 Q3	–	Sell	-10,000	Closed	-$489K	–	116
2016 Q2	$489K	Sell	10,000 -30,000	-75%	-$1.94M	0.09%	91
2016 Q1	$2.53M	Buy	+40,000	New	+$2.62M	0.5%	69

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Rhenman & Partners Asset Management's RARE Position: Q4 2025 in Review

Rhenman & Partners Asset Management sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2025, closing a stake of 119,400 shares — an estimated $3.59M sold.

Rhenman & Partners Asset Management first reported a position in RARE in Q1 2016 and held it in 11 quarters. The position peaked at $5.33M in Q3 2017. 287 funds tracked by Wall St. Rank hold RARE as of Q4 2025.

Rhenman & Partners Asset Management reported no remaining Ultragenyx Pharmaceutical position as of Q4 2025 after selling out during the quarter.
Rhenman & Partners Asset Management sold 119,400 Ultragenyx Pharmaceutical shares in Q4 2025, an estimated $3.59M.
Rhenman & Partners Asset Management first reported a position in Ultragenyx Pharmaceutical in Q1 2016 and held it in 11 quarters.
Rhenman & Partners Asset Management's Ultragenyx Pharmaceutical position peaked at $5.33M in Q3 2017.
287 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2025.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.